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Background: Manipulations in Saccharomyces cerevisiae classically depend on use of auxotrophy selection markers.
There are several disadvantages to this in a microbial cell factory setting: (1) auxotrophies must first be engineered
in prototrophic strains, and many industrial strains are polyploid/aneuploid prototrophs (2) available strain
auxotrophies must be paired with available repair plasmids (3) remaining auxotrophies must be repaired prior to
development of industrial bioprocesses. Use of dominant antibiotic resistance markers can circumvent these
problems. However, there are relatively few yeast antibiotic resistance marker vectors available; furthermore,
available vectors contain only one expression cassette, and it is often desirable to introduce more than one gene at
a time.
Results: To overcome these problems, eight new shuttle vectors have been developed. The plasmids are
maintained in yeast under a 2 μm ori and in E. coli by a pUC ori. They contain two yeast expression cassettes driven
by either (1) the constitutive TEF1 and PGK1 promoters, or (2) the constitutive TEF1 promoter and the inducible
GAL10 or HXT7 promoters. Expression strength of these promoters over a typical production time frame in glucose/
galactose medium was examined, and identified the TEF1 and HXT7 promoters as preferred promoters over long
term fermentations. Selection is provided by either aphA1 (conferring resistance to G418 in yeast and kanamycin/
neomycin in E. coli) or ble (conferring resistance to phleomycin in both yeast and E. coli). Selection conditions for
these plasmids/antibiotics in defined media were examined, and selection considerations are reviewed. In particular,
medium pH has a strong effect on both G418 and phleomycin selection.
Conclusions: These vectors allow manipulations in prototrophic yeast strains with expression of two gene cassettes
per plasmid, and will be particularly useful for metabolic engineering applications. The vector set expands the
(currently limited) selection of antibiotic marker plasmids available for use in yeast, and in addition makes available
dual gene expression cassettes on individual plasmids using antibiotic selection. The resistance gene cassettes are
flanked by loxP recognition sites to allow CreA-mediated marker removal and recycling, providing the potential for
genomic integration of multiple genes. Guidelines for selection using G418 and phleomycin are provided.
Keywords: Saccharomyces cerevisiae, Expression vector, Antibiotic selection, G418, Phleomycin, Yeast* Correspondence: c.vickers@uq.edu.au
Australian Institute for Bioengineering and Nanotechnology
The University of Queensland, Brisbane St Lucia QLD 4072, Australia
© 2013 Vickers et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Vickers et al. Microbial Cell Factories 2013, 12:96 Page 2 of 10
http://www.microbialcellfactories.com/content/12/1/96Background
Saccharomyces cerevisiae is a model organism and an in-
dustrial workhorse. It is readily transformed with plas-
mid expression vectors, and is therefore particularly
amenable to functional analysis experiments and genetic
engineering applications. Plasmid vectors may be inte-
grative (yeast integrating plasmids, YIp), autonomously
replicating high copy-number vectors (yeast episomal
plasmids, YEp), or autonomously replicating low copy-
number vectors (yeast centromeric plasmids, YCp) [1,2].
Typically, selection for presence/genomic integration of
the plasmid is performed by complementation/repair of
a chromosomal mutation resulting in auxotrophy for an
amino acid. Commonly-used markers include URA3,
HIS3, LEU2, TRP1 and LYS2. A wide variety of yeast
strains containing one or several mutations with low re-
version rates conferring appropriate auxotrophies are
available (e.g. ura3-52, his3-Δ1, leu2-Δ1, trp1-Δ1 and
lys2-201 [1]; see the Saccharomyces Genome Database,
http://www.yeastgenome.org/). However, to use these
strains one must have a plasmid bearing an appropriate
auxotrophy gene, and vice-versa: the plasmid bearing a
particular gene of interest must encode an auxotrophy
repair gene for which the cognate auxotrophy is found
in the strain of interest. This may not be the case, par-
ticularly in heavily engineered strains where more genes
are being introduced, as auxotrophies may already
be complemented/repaired. Furthermore, any remaining
auxotrophies must be repaired in engineered strains for
which industrial bioprocesses are being developed (e.g.
[3]). In addition, wild-type and industrial strains are typ-
ically polyploid or aneuploid prototrophs [4]. Engineer-
ing in prototrophs requires use of dominant markers
and/or time-consuming construction of auxotrophy mu-
tants, which may be difficult or impossible in a complex
genetic background.
An alternative to using auxotrophies is to use domin-
ant resistance markers. Selection genes conferring resist-
ance to various substances are available (reviewed in
[2,5]). Among these, resistance to antibiotics is most
commonly used. The antibiotics G418 [6-10], hygromy-
cin B [8-14], phleomycin [15], chloramphenicol [16],
nourseothricin [8,13,14], bialaphos [13], zeocin [9], glu-
fosinate [9] and aureobasidin A [17] can be used for se-
lection of S. cerevisiae transformed with appropriate
resistance genes, and shuttle vectors conferring resist-
ance to several of these antibiotics (or equivalents) in
E. coli have also been developed. However, the yeast
community has historically used auxotrophy repair/com-
plementation more widely than antibiotic selection be-
cause of the insensitivity of yeast to many antibiotics
and the frequency of spontaneous resistant mutants
[18]. Furthermore, the efficiency of transformation and
transformant recovery is often lower using antibioticmarker selection. Nowadays, antibiotic resistance vectors
that provide improved transformant selection are avail-
able (e.g. [19]), and greatly improved yeast transform-
ation methods (e.g., [20]) as well as improved antibiotic
selection methods (e.g. [21]) mean than efficiencies simi-
lar to those obtained using auxotrophy selection can be
achieved.
Current antibiotic selection plasmids typically contain
only one gene expression cassette. However, it is often
desirable to introduce more than one gene at a time,
particularly for metabolic engineering projects where
multiple modifications and/or complex pathway recon-
struction is required. Several dual gene expression cas-
sette vectors have been developed [22-26], as have single
gene expression vectors that can be used combinatorially
for metabolic engineering applications [27]. However,
all of these vectors rely on auxotrophy selection markers.
Currently, to our knowledge there are no dual expres-
sion vector plasmids with antibiotic selection available.
Here, we describe development of dual gene expression
shuttle vectors for yeast transformation/engineering using
dominant antibiotic marker genes. Antibiotic selection
characteristics of S. cerevisiae strains bearing these plas-
mids were examined, and guidelines for antibiotic use in
defined media are provided.
Results and discussion
Vector construction and promoter analysis
Partow et al. (2010) recently developed a pair of dual cas-
sette expression vectors for use in glucose-containing
media. They replaced the bi-directional galactose-
inducible GAL1-GAL10 promoter region in pESC-Ura
(Stratagene; now supplied by Agilent Technologies
http://www.genomics.agilent.com) with a TEF1-PGK1
bi-directional promoter developed from the transcrip-
tional elongation factor EF-1α (TEF1) and phospho-
glycerate kinase (PGK1) promoters. These glycolysis
gene promoters perform well on glucose-based media
in S. cerevisiae CEN.PK-derived strains [22]. Two vec-
tors (pSP-G1 and pSP-G2) were constructed, with the
bi-directional promoter in both orientations relative to the
multiple cloning site and terminator sequences (either
ADH1 or CYC1 terminators from S. cerevisiae) [22].
To develop dual gene expression shuttle vectors for
yeast transformation/engineering with dominant anti-
biotic marker genes, we replaced the uracil auxotrophy
selection marker (URA3) in pSP-G1 and pSP-G2 with
either aphA1 or ble cassettes flanked by loxP recombin-
ation sites from pUG6 or pUG66 [28-30] respectively.
The aphA1 gene confers resistance to kanamycin (in E.
coli) and G418 (in yeast); the ble gene confers resist-
ance to phleomycin in both E. coli and yeast. Gene re-
placement resulted in four different plasmids with all
























Figure 1 Generic plasmid vector map for the pCEV dual gene
cassette expression vectors. Each plasmid has two expression
cassettes, each driven by a different promoter (P1 or P2), and a
selection cassette with either aphA1 or ble genes. Promoter/selection
combinations are shown in Figure 1. Each gene of interest can be
optionally tagged using either a FLAG epitope tag (Expression
Cassette 1) or a c-myc epitope tag (Expression Cassette 2). The
selection cassette is controlled by the TEF promoter and terminator
from Ashbya gossypii (PAgTEF1 and TAgTEF1). The terminator for
Expression Cassette 1 is derived from the yeast alcohol
dehydrogenase (AHD1) gene. The terminator for Expression Cassette
2 is derived from the yeast cytochrome C (CYC1) gene. The potential
exists for integration of the expression cassettes onto the
chromosome by amplification using primers with homologous arms;
in this case, the selection marker cassette can be removed to recycle
the marker via CRE-mediated recombination at the available loxP
sites. A pUC origin of replication (Ori) is available for maintenance in
E. coli and a 2 μm Ori for maintenance in S. cerevisiae. Selection in E.
coli can be performed using either the aphA1/ble selection cassette,
which is functional for selection in E. coli, or using the beta-
lactamase (bla) ampicillin resistance gene. The dual promoter region
is not to scale (size varies depending on which promoters are
present) and the selection marker is also not to scale (can be either
aphA1 or ble). Different vector components in these two regions, as
well as the unique restriction enzyme sites found in each multiple
cloning site (MCS), are shown in Table 2. Note that the MCS spans
the epitope tag sites for each expression cassette; choice of
restriction sites will determine whether or not the tag sequence is
retained in the construct.
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G2-Ph and pCEV-G2-Km (Figure 1, Table 1).
In contrast to Partow et al. (2010), who examined pro-
moter strength in CEN.PK-derived strains, we observed
unexpectedly poor expression strength when using the
PGK1 expression cassette in our vectors with S288C-
derived strains (data not shown). We therefore examined
the relative strength of several promoters using a β-
galactosidase reporter gene assay in an S288C-derived
strain. As well as the TEF1 and PGK1 promoters, we in-
cluded the GAL10 promoter, since the S288C-derived
strain EPY210C [31] that we were using also has
galactose-inducible modifications, and we were inter-
ested in using this promoter for future engineering
experiments. In addition, we tested a high affinity hex-
ose transporter (HXT7) promoter [22]. The HXT7
gene is up-regulated when glucose concentrations are
low and repressed when glucose concentrations are
high [22,32-34], and therefore provides a potential al-
ternative for driving gene expression in media with
low/no glucose - including galactose or glucose/galact-
ose medium used for GAL promoter-driven expression
(e.g., [3,35-37]). Available promoter:β-galactosidase yeast
integrating plasmids were used for the TEF1 and PGK1
promoters [22], and similar plasmids were constructed for
the HXT7 and GAL10 promoters (see Methods).
Reporter gene activity driven by the TEF1, PGK1,
GAL10 and HXT7 promoters was examined over several
days in cultures grown on rich medium containing 0.2%
glucose + 1.8% galactose (Figure 2). This sugar combin-
ation is used to build up biomass prior to inducing ex-
pression of desired genes (e.g. [3,35,37]). In this
medium, glucose is rapidly consumed within the first 6–
8 hours of fermentation; growth then shifts to being
galactose-based. This experiment confirmed that the
PGK1 promoter drives relatively poor expression in S.
cerevisiae S288C-derived strains growing on galactose.
Over the short term (24 hr, by which time cultures are
in stationary phase), the TEF1 promoter emerged as the
strongest promoter, with the GAL10 and HXT7 pro-
moters driving slightly lower, but similar levels of ex-
pression. By the third day, β-galactosidase activity was
similar for the TEF1, GAL10 and HXT7 promoters. By
day 7, the TEF1 and HXT7 promoters were still driving
good levels of expression, while β-galactosidase activity
driven by the GAL10 promoter was much weaker. De-
pending on the time scale of the fermentation and rela-
tive stability of the gene products, both the GAL10 and
HXT7 promoters show utility for glucose/galactose fer-
mentations using S288C-derived strains. We therefore
replaced the weak PGK1 promoter with GAL10 or
HXT7 promoters. This resulted in four new dual gene
expression plasmids (Table 1, Figure 1). In plasmids con-
taining the GAL10-controlled expression cassette(pCEV-G3-Km and pCEV-G3-Ph), the potential exists to
generate a third expression cassette by inserting an MCS
and a terminator sequence between the bidirectional
GAL10-1 promoter region and the TEF1 promoter. This
third expression cassette would be controlled by the
GAL1 promoter. Genes already fused to a terminator
can be placed under the control of the GAL1 promoter
by insertion through the unique FseI restriction site in
pCEV-G3-Ph, or the unique FseI, KroI, NaeI or NgoMIV
restriction sites in pCEV-G3-Km.




Expression cassette 1 Expression cassette 2 Selection
marker
GenBank
accessionPromoter Unique RE sites Promoter Unique RE Sites
pCEV-G1-Km TEF1 NotI, SpeI, PacI PGK1 BamHI, ApaI, ApaI, XmaI, SalI, Acc65I, KnpI, SacII, NheI aphA1 KF366478
pCEV-G1-Ph TEF1 NotI, SpeI, PacI PGK1 BamHI, ApaI, HindIII, Acc65I, KnpI, SacII, NheI ble KF366479
pCEV-G2-Km PGK1 NotI, SpeI, PacI TEF1 BamHI, ApaI, ApaI, XmaI, SalI, Acc65I, KnpI, SacII, NheI aphA1 KF366480
pCEV-G2-Ph PGK1 NotI, SpeI, PacI TEF1 BamHI, ApaI, HindIII, Acc65I, KnpI, SacII, NheI ble KF154123
pCEV-G3-Km GAL10 SpeI, PacI TEF1 BamHI, ApaI, ApaI, XmaI, SalI, Acc65I, KnpI, SacII, NheI aphA1 KF366481
pCEV-G3-Ph GAL10 SpeI, ClaI, PacI TEF1 BamHI, ApaI, HindIII, Acc65I, KnpI, SacII, NheI ble KF366482
pCEV-G4-Km HXT7 SpeI, PacI TEF1 BamHI, ApaI, XmaI, SalI, Acc65I, KnpI, SacII, NheI aphA1 KF366483
pCEV-G4-Ph HXT7 SpeI, ClaI, PacI TEF1 BamHI, HindIII, Acc65I, KnpI, SacII, NheI ble KF366484
Unique restriction sites are shown for commonly-found restriction enzymes (RE) in the multiple cloning site for each expression cassette (other unique sites are
also present). Plasmid datasheets are available in the Additional file 1. Plasmid maps in Clone Manager format (Sci-Ed Software, http://www.scied.com) are
available through the AddGene website (http://www.addgene.org/).
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In the process of applying the expression vectors for
yeast engineering projects, we learned a number of
things about using G418 and phleomycin as selective
agents. In particular, we observed plasmid instability
and poor selection on defined media. For all 2 μ plas-































Figure 2 β-Galactosidase activity driven by various promoters
in the S. cerevisiae S288C-derived strain EPY210C growing on
galactose. EPY210C [31] was used as a base for strain construction
to test promoter expression strength using promoter:lacZ constructs
on integrative plasmids. Plasmids pSF015 (HXT7 promoter), pSF016
(PGK1 promoter), and pSF019 (TEF1 promoter), bearing promoters
amplified from S. cerevisiae CEN.PK, have been described previously
[22]. We reconstructed a PGAL10: lacZ fusion construct (pGAL10lac) by
amplifying the relevant region from S. cerevisiae S288C genomic
DNA (see Methods). The negative control was the promoterless lacZ
plasmid pSF011 [22]. β-Galactosidase assays are described in the
Methods. Bars are means of n = 3 biological replications; errors are
standard deviations.in non-selective medium (data not shown); we have
previously observed this for 2 μ auxotrophy selection
plasmids as well [31]. We have summarized our obser-
vations, along with a review of the relevant literature,
in the sections below. In addition, we did a detailed
study on the effects of pH on selection.
G418
The aphA1 gene from the E. coli transposon Tn903
[38] encodes an aminoglycoside 3′-phosphotransferase
activity which confers resistance against G418 (sold as
Geneticin® by Invitrogen/Life Technologies) in S. cerevisiae
and kanamycin in E. coli [4,6,18,39]. It is also referred
to as kan (for kanamycin resistance), neo (for neomycin re-
sistance) or npt1 (for neomycin phosphotransferase). G418
and kanamycin are 2-deoxystreptamine aminoglycoside an-
tibiotics; they act by inhibition of protein translation at the
elongation step [40]. The level of resistance conferred de-
pends on several factors, including expression strength and
copy number. The kanMX module [39] contains aphA1
(kan) under the control of promoter and terminator se-
quences from the TEF gene of the filamentous fungus Ash-
bya gossypii. It confers resistance to G418 at 200 μg/mL in
S. cerevisiae grown on YPD (YEPD) and kanamycin at 30
μg/mL in E. coli grown on LB. This cassette was subse-
quently flanked by loxP sites to allow facile marker gene
removal during knock-out and tagging experiments via the
CRE-loxP recombination system [28]. The kanMX loxP
construct was used in the current work for plasmid
assembly.
Medium composition affects the efficiency of G418 selec-
tion [18]. In particular, pH has a strong effect on aminogly-
coside phosphotransferase activity [41]; therefore, medium
pH may modulate selective pressure. Activity is higher at
pH 7 than at decreased pH such is found in typical defined
yeast media (often around 5.5; [42,43]). While selection in
complex YPD medium is effective at 200 μg/mL G418 in
YPD, we encountered problems when using defined media.
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conditions, we tested growth on defined medium with the
pH adjusted to either 5 or 7 and supplemented with a range
of G418 concentrations (Table 2). At both pH 5 and pH 7,
selection was ineffective at 200 μg/mL G418. Effective
selection could be achieved at 400 μg/mL G418 at both pH
values. This indicates that the aminoglycoside transferase
activity was in fact similar under both pH conditions, and
that some other medium component/condition affects
selectivity at concentrations below 400 μg/mL G418. In
addition to pH, ammonium sulphate is known to interfere
with G418 selection; it can be replaced with monosodium
glutamate at 1 g/L to improve selection characteristics
without modifying medium pH [44].
It should also be noted that G418 efficiency can de-
crease at high cell densities in mammalian cells [45]; this
can presumably occur in yeast as well. In addition, com-
mercial G418 preparations can vary in purity and po-
tency, even in between batches [28]. In summary, the
following considerations should be taken into account
when using G418 as a selective agent:
1. Medium pH should be considered, as
aminoglycoside transferase activity decreases with
decreasing pH.
2. Medium composition affects selection conditions.
3. Selection conditions may vary with strain.
4. Loss of G418 resistance may occur over long
incubation periods; this is most likely related to high
culture density. Dosing in more antibiotic may
improve selection over long cultivations to prevent
plasmid loss.
5. Plating density may also affect selection.
6. Growth rates may decrease in the presence of G418.
7. Adjusting the pH to neutral or increasing antibiotic
concentrations may be required.
Phleomycin
The ble gene from the bacterial transposon Tn5 confers
resistance to the metallo-glycopeptide class antibiotics
bleomycin and phleomycin in both prokaryotes andTable 2 Antibiotic sensitivity testing
pH Strain G418 (μg/mL)
200 400 600
5
S288C +++ - -
EPY210C(pCEV-G2-Ph) +++ - -
EPY201C(pCEV-G2-Km) +++ +++ +++
7
S288C +++ - -
EPY210C(pCEV-G2-Ph) +++ - -
EPY201C(pCEV-G2-Km) +++ +++ +++
Strains were streaked onto SD medium with pH adjusted to either 5 or 7, and supp
large colonies; ++, slow growth, small colonies; +, very poor growth in primary inoceukaryotes [15,46-48]. These antibiotics act by binding
to DNA and causing strand breakage [49-51]. Efficient
DNA binding and breakage requires metal ions (ferrous
ions) and molecular oxygen as cofactors [50,51]. Accord-
ingly, S. cerevisiae is significantly more resistant to
phleomycin under anaerobic conditions [15], and pres-
ence of EDTA decreases/removes toxicity [52]. Sen-
sitivity to phleomycin depends on growth phase in
S. cerevisiae: stationary phase cells are less sensitive than
exponentially growing cells [52].
The Ble protein inactivates phleomycin family antibi-
otics by binding to them [53]. The ble gene was first devel-
oped as a selective marker for phleomycin resistance in S.
cerevisiae by Gatignol et al. [15]. The aphA1 gene in the
kanMX module was replaced by the ble gene to develop a
second TEF1 promoter-driven dominant marker gene
knock-out cassette [29]. This construct conferred
resistance to 7.5 μg/mL phleomycin in S. cerevisiae (CEN.
PK2-1C) growing on YPD. In early studies, incubation in
non-selective medium prior to application of selection
pressure was required to obtain transformed cells with
reasonable efficiency [21], though Gueldener et al. [29]
later found that pre-incubation did not enhance trans-
formation efficiency. This may be due to genotypic differ-
ences between yeast strains (OL1 in the former study and
CEN.PK-derived in the latter study), differences in expres-
sion characteristics (CYC1 promoter in the former vs.
TEF1 in the latter) and/or differences in growth media. In
our hands, we found that a three hour incubation in non-
selective medium is optimal for efficient transformation in
the S288C-derived strain EPY210C being selected on YPD
(data not shown). Plating at high densities can also de-
crease transformation efficiency [21].
Most commercial preparations of phleomycin suggest
using 10 μg/mL for selection of S. cerevisiae on YPD, as
determined by Gatignol et al. [19]. However, we ob-
served colonies of S288C-derived strains (without plas-
mid) on YPD plates containing phleomycin at 10 μg/mL
after three days (data not shown). This suggests that
spontaneous resistance can develop over that timeframe
under those conditions. Increasing the concentration toPhleomycin (μg/mL)
800 20 40 60 80 100
- +++ +++ ++ ++ +
- +++ +++ +++ +++ +++
+++ +++ +++ ++ ++ +
NT ++ - - NT NT
NT +++ +++ +++ NT NT
NT ++ - - NT NT
lemented with antibiotics at the concentrations noted. +++, strong growth,
ulum region only, no defined colonies; -, no growth. NT = not tested.
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using 20 μg/mL completely inhibited development of
spontaneous resistance over a seven day period (data not
shown).
Phleomycin sensitivity decreases at lower pH values
[54], such as commonly found in defined yeast media
[42,43]. We therefore examined selection efficiency in
defined medium at pH 5 and 7, again using several dif-
ferent concentrations of phleomycin (Table 2). Selection
was essentially ineffective at pH 5. Some selective pres-
sure was observed at 60–80 µg/mL; selective pressure
increased significantly at 100 µg/mL, but growth was
not completely repressed in control strains even at 100
µg/mL. When the pH was adjusted to 7, selection was
highly effective at concentrations at or above 40 µg/mL.
We also observed that the TEF1 promoter-driven ble
module could confer resistance to phleomycin in E. coli
(data not shown), as shown for other yeast ble con-
structs [15]. This allows dual antibiotic selection of
transformed E. coli (using ampicillin at 100 μg/mL and
phleomycin at 5 μg/mL).
In summary, the following considerations should be
taken into account when using phleomycin as a selective
agent:
1. Phleomycin activity requires the presence of
molecular oxygen and ferrous ions. Anaerobic
fermentations may require significantly higher
phleomyin concentrations.
2. Plating at high densities can decrease transformation
efficiency.
3. Depending on strain/medium, efficient selection may
require incubation on non-selective medium prior to
application of selective pressure, and may also affect
maintenance of selection.
4. Sensitivity to phleomycin decreases below neutral
pH. Phleomycin concentration may need to be
increased significantly in media with lower pH
values; ideally, medium pH should be adjusted to 7.
5. Antibiotic titration/dosing may be required during
prolonged cultivations to prevent development of
spontaneous resistance and/or plasmid loss.
6. Stationary phase cells are less sensitive to
phleomycin than exponentially growing cells.
Conclusions
In summary, we have developed dominant marker plas-
mids containing two gene expression cassettes that pro-
vide selection in Saccharomyces cerevisiae via either
phleomycin or G418 resistance. A caveat of using G418
and phleomycin for selection is the requirement for ad-
justment of medium pH to neutral and/or increasing
antibiotic concentration to maintain selective pressure
on defined media. Expression of genes in each plasmidcan be controlled by a combination of the TEF1 pro-
moter with either the PGK1, GAL10 or HXT7 pro-
moters. Each promoter is followed by a multiple cloning
site (MCS) and a transcription termination sequence. In
addition, both expression cassettes encode epitope tags
that can be used for C- or N-terminal tagging. The plas-
mids are shuttle plasmids with a 2 μm ori (yeast) and a
pUC ori (E. coli). Selection in E. coli is conferred by a
beta-lactamase (bla) ampicillin resistance gene as well as
the aphA1 or ble genes. The TEF1, GAL10 and HXT7
promoters drive strong expression in galactose medium;
TEF1 and HXT7 are preferred for high expression over
prolonged fermentations. The HXT7 promoter might
also be useful in other non-/low-glucose media (e.g.
sucrose-based media). We have subsequently used these
plasmids successfully for expression of isoprenoid pro-
duction genes in yeast (data not shown). Genomic inte-
gration of the expression and selection cassettes could
be readily achieved by amplification using primers with
suitable homologous arms [55]. PCR-mediated integra-
tion of similarly large fragments has been demonstrated
recently, and useful integration loci have been character-
ized [23,27]. The presence of the loxP sites allows re-
moval of selective marker genes by CreA-mediated
recombination so they can be re-used for subsequent
modifications [28,55]. The aphA1 or ble genes can also
be replaced by genes encoding alternative selection func-
tions (e.g., see review in Introduction) to expand the
available selection systems. The antibiotic marker vec-
tors can also be used to pyramid further modifications
into strains where available auxotrophy markers have
been exhausted by insertion of multiple constructs. In
addition, they may also be useful in other yeasts and fila-
mentous fungi that are sensitive to phleomycin or G418;
for example, the yeasts Schizosaccharomyces pombe [56]
and Cryptococcus neoformans [57] and the filamentous
fungi Aspergillus flavus [54], Neurospora crassa [58], As-
pergillus nidulans [58] and Pleurotus ostreatus [59] are
all sensitive to phleomycin. The plasmids are available
through AddGene (http://www.addgene.org/) and Euro-
scarf (http://web.uni-frankfurt.de/fb15/mikro/euroscarf/).
Detailed plasmid datasheets are available in Additional
file 1 and annotated sequence files in Clone Manager
format (Sci-Ed Software, http://www.scied.com) are avail-
able through the AddGene website (http://www.addgene.
org/). Sequence data can also be downloaded from Gen-
Bank using the provided accession numbers (Table 1).
Methods
Strains and media
E. coli strain MG1655 (Coli Genetic Stock Centre
CGSC#7740, New Haven CT, USA) or α-select (Bioline;
Alexandria NSW, Australia) were used for plasmid ma-
nipulations; they were maintained on LB medium [60],
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formation according to the manufacturer’s instructions.
S. cerevisiae S288C was kindly provided by the Austra-
lian Wine Research Organisation, and was originally
sourced from the American Type Culture Collection
(http://www.atcc.org/; ATCC Accession: 204508). The
S288C-derived S. cerevisiae strain EPY210C [31] was
used as a base for strain construction to test promoter
expression strength (see below). S. cerevisiae strains were
grown on YPD [43] for general growth and selection,
and on YPD with the glucose replaced with 0.2% glucose
and 1.8% galactose (YPDG) for promoter analysis experi-
ments (see below). To examine the effect of pH on se-
lective power in defined medium, yeast were grown in
SD medium [43] with the pH adjusted to either 5 or 7
(using potassium hydroxide) and filter-sterilised. All
media were supplemented with appropriate antibiotics at
the concentrations stated. Antibiotics G418 sulfate and
Phleomycin were sourced from Invivogen (San Diego,
California; cat. # ant-gn-5 and ant-ph-5, respectively).
Plasmids and plasmid construction
The uracil auxotrophy selection marker in pSP-G1 and
pSP-G2 [22] was replaced with either aphA1 or ble
cassettes containing loxP recombination sites from




















SFB017 GAGACGATATATGCCAATACTTCrespectively. pUG6 and pUG66 were prepared for use as
PCR templates by digesting with BglI. The digested plas-
mids were used as PCR templates with primers HA1-
kanphleo and HA2-kanphleo (Table 3). For HA1-
kanphleo, the 5′ sequence is homologous with sequence
just downstream from the 2 μm ori pUG6/pUG66. The
SalI site in pUG6 is destroyed, but the AccI site (under-
lined) remains for facile removal of the cassette. For
HA2-kanphleo, the 5′ sequence is homologous with se-
quence at the end of the ADH1 terminator in pUG6/
pUG66. The sequences in italics are the priming sites in
pUG6/pUG66. Resulting PCR products have arms that
are homologous to sequences upstream and down-
stream of the URA marker in pSP-G1 and pSP-G2; re-
placement of the URA3 gene with the kanMX or ble
cassettes removes the F1 ori in pSP-G1/pSP-G2. PCR
products were digested with DpnI. The vectors (pSP-
G1/pSP-G2) were prepared by digestion with EcoRV
and NcoI and then cleaned. Fragments were trans-
formed into electro-competent E. coli MG1655 cells
harbouring the λ Red recombinase plasmid pKD46 [61]
for cloning by homologous recombination (‘recombi-
neering’; [62,63]). Selection was performed on ampicil-
lin (100 μg/mL) plus either kanamycin (30 μg/mL) or
phleomycin (5 μg/mL). Clones were screened by colony
PCR using primers 2muDown and ADH1-T F1 (Table 3).Application/notes
ACTTCGTA) Cloning of antibiotic resistance gene cassettes.
Sequences in italics are priming sites in pUG6/pUG66.
For HA1-kanphleo, the 5′ sequence is homologous with
sequence just downstream from the 2 μm ori pSPG1/
pSPG2; the SalI site in pUG6 is destroyed, but the AccI
site (underlined) remains for facile removal of the
cassette. For HA2-kanphleo, the 5′ sequence is
homologous with sequence at the end of the ADH1
terminator in pSPG1/pSPG2.
C
Screening colonies and sequencing for pCEV-G1-Ph,
pCEV-G1-Km, pCEV-G2-Ph and pCEV-G2-Km
AAAGTA Amplification of GAL10-GAL1 promoter region from S.
cerevisiae S288C. The sequence in italics is homologous
to the target vector pSF011 [22]. Restriction enzyme
sites are underlined. The remaining sequence is the
priming site for S. cerevisiae S288C genomic DNA.
ACTTTTTTTTTG
Amplification of the GAL promoter region from
pGAL10lac. Restriction sites are underlined and priming
sequence is italicised
Amplification of the HXT7 promoter from pSF015 [22].
Restriction sites are underlined and priming sequence is
italicised
Screening for promoter:lacZ yeast strains
Screening for pCEV-G3 and pCEVG4 constructs
Screening for pCEV-G3 constructs
Screening for pCEV-G4 constructs
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restriction analysis and the insert fully sequenced using the
same primers. Resulting plasmids were pCEV-G1-Ph,
pCEV-G1-Km, pCEV-G2-Ph and pCEV-G2-Km.
Using pCEV-G2-Ph and pCEV-G2-Km as base plas-
mids, a second set of plasmids where the PGK1 pro-
moter was replaced with the strong galactose-inducible
GAL10 promoter or the HXT7 promoter (which is in-
duced at low glucose concentrations) was also con-
structed. The complete GAL10-GAL1 promoter region
was amplified from S. cerevisiae S288C using primers
GAL10LacF and Gal10LacR (Table 3). The pSF011 pro-
moterless target vector was opened using BamHI and
XbaI restriction sites and the amplified fragment with
homologous arms was cloned in by homologous recom-
bination as described previously [64] using E. coli strain
One Shot Omnimax 2 T1 (Life Technologies). The
resulting plasmid was called pGAL10Lac. The GAL10
promoter was then PCR-amplified from pGAL10Lac
using the primers GAL10P2B and GAL10P1A (Table 3).
The HXT7 promoter was PCR amplified from pSF015
[22] using the primers HXT7P1B and HXT7P2A (Table 3).
The PCR products and the vectors pCEV-G2-Km and
pCEV-G2-Ph were digested with FseI and SpeI; DpnI
was also included in the PCR fragment digests to elim-
inate template DNA. The vectors were purified by gel
extraction and the PCR products were purified through
a column (QIAquick PCR purification kit, Qiagen).
Ligation products were transformed into E. coli α-Select
Silver Efficiency chemically competent cells (Bioline).
Selection was performed on ampicillin (100 μg/mL).
Colonies were screened by PCR using ADH1-T R1
paired with either SFB018 for pCEV-G3 constructs or
SFB017 for pCEV-G4 constructs (Table 3). Plasmids
were confirmed by restriction analysis and sequencing.
The resulting plasmids were pCEV-G3-Km, pCEV-G3-Ph,
pCEV-G4-Km and pCEV-G4-Ph.
The promoter:lacZ integrative plasmids pSF015 (HXT7
promoter), pSF016 (PGK1 promoter), and pSF019 (TEF1
promoter), as well as the promoterless lacZ control
integrative plasmid pSF011, were kindly provided by
Prof. Jens Nielsen (Chalmers University of Technology,
Sweden). These constructs have been described previ-
ously [22]. The Partow et al. (2010) study also included
GAL1 and GAL10 promoters isolated from S. cerevisiae
CEN.PK; we reconstructed the PGAL10:lacZ fusion con-
struct by amplifying the relevant regions from S. cerevi-
siae S288C genomic DNA using GAL10LacF and
GAL10LacR primers (Table 3). The pSF011 plasmid was
opened using BamHI and XbaI restriction sites and am-
plified fragments with homologous arms were cloned in
by homologous recombination as described previously
[64] using E. coli strain One Shot Omnimax 2 T1 (Life
Technologies). The GAL promoter region was cloned as acomplete region (PGAL1 + PGAL10 in divergent orientations)
and inserted in the GAL10 orientation to produce
pGAL10Lac.
Strain construction
S. cerevisiae transformation was performed using the
lithium acetate method [20]. For YEp dominant marker
plasmids, transformants were selected on YPD supple-
mented with 200 μg/mL G418 or 20 μg/mL phleomycin
after a three hour pre-incubation period on non-
selective medium. Integrative plasmids were linearized
using NcoI prior to transformation. Selection was per-
formed on uracil SD drop-out agar (Sigma-Aldrich;
Sydney, Australia) supplemented with 2% glucose. For
all transformations, biological replicates were generated
as described previously [65]; briefly, three individual col-
onies were selected from the transformation plates and
denoted as biological replicates for each new strain. Col-
ony PCR was performed using primers CYC1-TR1
(GGGACCTAGACTTCAGGTTGTC) and Lac9434r (G
AAGCCTGCGATGTCGGTTTC). Each biological repli-
cate was purified by streaking out on uracil SD drop-
out agar and inoculated into 5 mL SD uracil drop-out
broth (Sigma-Aldrich; Sydney, Australia) supplemen-
ted with 2% glucose. Cultures were grown overnight at
30°C, 200 rpm. Glycerol stocks were prepared in 20%
glycerol and stored at -80°C.
For antibiotic sensitivity testing, EPY210C was trans-
formed with pCEV-G2-Ph and pCEV-G2-Km to generate
EPY210C(pCEV-G2-Ph) and EPY201C(pCEV-G2-Km), re-
spectively. Biological replicates and glycerol stocks were
produced as described above. To confirm plasmid pres-
ence, plasmid was extracted from each strain and veri-
fied by PCR.
β-galactosidase assays
For β-galactosidase assays, glycerol stocks were streaked
out on solid YPD and grown at 30°C. Single colonies
(three per strain; technical replications) were inoculated
into 5 mL YPD broths and cultured overnight at 30°C,
200 rpm. Overnight cultures were used to inoculate
30 mL YPDG to an OD660 of 0.2. Cultures were sampled
at 24 hr and again at 3 days and 7 days. To extract pro-
tein, 5 mL culture was centrifuged (3000 × g, 4°C, 5 min)
and the resulting pellet washed twice with ice-cold H2O.
The cell pellet was resuspended in 1 mL extraction
buffer (25 mM Tris–HCl, 1 mM DTT, 5 mM EDTA,
pH 7.5) containing 20 μL of protease inhibitor cocktail
(Sigma-Aldrich; Sydney, Australia) and the resulting
suspension transferred to a pre-chilled 2 mL tube half
filled with acid-washed glass beads (Ø = 0.5 mm). Cells
were disrupted with a Mini Beadbeater-1 (Biospec
Products, Bartlesville, OK, USA) using 4 x 20 s bead-
beating bursts at 4800 oscillations per minute with
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rupted cells were centrifuged (13 000 × g, 4°C, 5 min)
and the supernatant collected. Protein concentration
was determined by the method of Bradford [66] using
a BioRad Protein Assay kit (BioRad, Gladesville, NSW,
Australia) and bovine serum albumin as a standard.
β-Galactosidase assays were performed using high-
throughput microtitre plate method as described pre-
viously [67] with minor modifications, including use of
a kinetic approach for the enzyme assay and standard-
isation to extract protein concentration. Briefly, 5 μL
of supernatant extract was added in triplicate to mi-
crotitre plate wells containing 85 μL Z buffer [68]. The
reaction was initiated by adding 10 μL 4 mg/mL O-ni-
trophenyl-β-D-galactoside (ONPG) prepared in phos-
phate buffer. The reaction was monitored at 37°C
using a FLOUstar Omega plate-reading spectropho-
tometer (BMG Labtech, Mornington, VIC, Australia)
for at least 30 min. The initial linear phase (normally within
the first 8 min of the reaction) was used to calculate the
rate. β-Galactosidase activity was expressed as ΔA450/min/
mg protein. S. cerevisiae EPY210C transformed with line-
arised pSF011 was used as a negative control.
Antibiotic sensitivity testing
Antibiotic sensitivity was tested using solid SD medium
with the pH adjusted to either 5 or 7, supplemented with
G418 at 200, 400, 600 or 800 µg/mL, or with phleomycin at
20, 40, 60, 80 or 100 µg/mL. Wild type S288C was used as
a negative control, EPY210C(pCEV-G2-Ph) and EPY201C
(pCEV-G2-Km) were used as representative strains bearing
phleomycin and G418 resistance plasmids, respectively.
Strains were streaked out on SD medium with the pH ad-
justed to 7; for EPY210C(pCEV-G2-Ph), the medium was
supplemented with 20 µg/mL phleomycin, and for
EPY201C(pCEV-G2-Km) the medium was supplemented
with 200 µg/mL G418. Plates were grown for 2 d at 30°C.
Single colonies from all three strains were streaked out on
the various SD media described above and incubated at
30°C for 3 days to test antibiotic selection characteristics.
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